Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
3
×
fda
life sciences
national blog main
national top stories
new york top stories
3
×
san francisco top stories
boston blog main
boston top stories
europe top stories
national
new york blog main
san diego blog main
san diego top stories
san francisco blog main
akcea therapeutics
alnylam pharmaceuticals
arena pharmaceuticals
barry greene
billy dunn
biogen
boston
boston university
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
dan ollendorf
detroit blog main
detroit top stories
drug prices
drug pricing
drugs
eisai
europe blog main
evrysdi
gene therapy
genentech
What
fda
medicine
3
×
patients
drug
friday
ago
alnylam
approve
approved
atrophy
awaits
biological
cancer
crossed
daily
decades
decision
discovered
eisai
evrysdi
fingers
flags
green
higher
historic
home
incidence
intended
lights
liquid
lorcaserin
loss
market
marketing
muscular
new
oral
post
pulls
risdiplam
Language
unset
Current search:
medicine
×
biotech
×
" new york top stories "
×
" clinical trials "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision